ImmunityBio, Inc. IBRX Reportable Segment — Interest Expense, Other
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by ImmunityBio, Inc. in its filing.
Tagged under the XBRL concept us-gaap:InterestExpenseOther.
The official record: ImmunityBio, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about ImmunityBio, Inc.'s reportable segment — interest expense, other.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is ImmunityBio, Inc.'s reportable segment — interest expense, other?
- ImmunityBio, Inc. (IBRX) reported reportable segment — interest expense, other of $13.87M in Q1 2026.
- How has ImmunityBio, Inc.'s reportable segment — interest expense, other changed year-over-year?
- ImmunityBio, Inc.'s reportable segment — interest expense, other increased by 2.5% year-over-year, from $13.53M to $13.87M.
- What is the long-term trend for ImmunityBio, Inc.'s reportable segment — interest expense, other?
- Over 2 years (2023 to 2025), ImmunityBio, Inc.'s reportable segment — interest expense, other has grown at a 867.9% compound annual growth rate (CAGR), from $264K to $24.73M.
- What does reportable segment — interest expense, other mean?
- Includes all interest-related costs not specifically categorized under related-party debt, such as interest on third-party loans, credit facilities, or lease liabilities. It represents the broader cost of servicing the company's debt obligations.